(HealthDay)—Fifty-five percent of children, adolescents, clonazepam and robitussin dm and young adults with hematologic malignancies experience high-intensity end-of-life care (HI-EOLC), with an increased likelihood for those treated at medium or large hospitals, according to a study published online June 29 in Cancer.
Sophia Mun, M.P.H., from the Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center in New Haven, Connecticut, and colleagues conducted a population-based retrospective cohort study involving individuals with hematologic malignancies aged 0 to 39 years at death, who died between 2010 and 2017. Patient sociodemographic and hospital characteristics associated with HI-EOLC were examined.
The researchers found that 55 percent of the 1,454 decedents experienced HI-EOLC. The likelihood of receiving HI-EOLC was increased for patients treated in medium or large hospitals (adjusted odds ratios, 1.63 and 2.21, respectively), insured by Medicaid (adjusted odds ratio, 1.40), or receiving cancer-directed treatment in the Northeast (adjusted odds ratio, 1.50).
“Insurance type, hospital size, and hospital region appear to significantly influence the receipt of HI-EOLC,” the authors write. “Mitigation strategies may include earlier integration of palliative and/or hospice care when feasible as well as a policy change that enables interventions such as transfusions to occur in settings outside the hospital.”
Source: Read Full Article